Leishmania energy metabolism enzymes

Leishmania energy metabolism enzymes are a diverse set of proteins essential for the parasite's survival, growth, and adaptation within the host [1.2.1]. These enzymes are primarily localized in two distinct compartments: the glycosomes, which house most glycolytic enzymes, and the single mitochondrion, which facilitates the Krebs cycle and oxidative phosphorylation [1.3.2]. Key pathways targeted for drug development include glycolysis, the pentose phosphate pathway, and the mitochondrial respiratory chain [1.2.1, 1.3.1]. Parasites rely on these enzymes to generate ATP and maintain redox homeostasis, particularly when transitioning between the insect vector and the mammalian host's macrophages [1.1.1, 1.4.3]. Several anti-leishmanial drugs, such as pentavalent antimonials and pentamidine, are known to interfere with these metabolic processes, leading to energy depletion and parasite death [1.3.1, 1.4.4]. Other experimental compounds, like buparvaquone and sitamaquine, specifically target mitochondrial complexes to disrupt electron transport [1.2.3, 1.4.1]. Despite their potential, targeting these enzymes is complicated by the structural similarities between certain parasite and host enzymes, which can lead to off-target toxicity [1.2.1, 1.4.1]. Additionally, the rapid emergence of drug resistance in Leishmania species necessitates the identification of more specific and potent metabolic inhibitors [1.1.2, 1.3.1].

Other names

Leishmania metabolic enzymesLeishmania bioenergetic enzymesGlycosomal and mitochondrial enzymes of LeishmaniaLeishmania glycolytic and respiratory enzymes

Inhibition of glycolytic enzymes such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), inhibition of mitochondrial respiratory chain complexes (e.g., Complex II and III), disruption of mitochondrial membrane potential, and inhibition of trypanothione reductase to impair redox homeostasis and ATP production [1.1.2, 1.2.3, 1.3.1].